Other
Increase in accrued expenses and other liabilities
Vertex Pharmaceuticals Increase in accrued expenses and other liabilities increased by 110.6% to $70.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 46.6%, from $48.10M to $70.50M.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests rising operational obligations or timing shifts in expense recognition, while a decrease indicates the settlement of these liabilities.
Detailed definition
This metric tracks the net change in obligations for expenses that have been incurred but not yet invoiced or paid. It i...
Peer comparison
Standard liability management metric; common in R&D-heavy firms with complex accrual structures.
Metric ID:
other_increase_decrease_in_accrued_liabilities_and_other_e28377Historical Data
17 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $146.70M | $51.20M | $61.60M | $485.50M | $433.20M | $107.35M | $107.35M | $107.35M | $107.35M | $194.10M | $168.30M | $170.60M | $48.10M | $166.60M | $332.90M | -$664.50M | $70.50M |
| QoQ Change | — | -65.1% | +20.3% | +688.1% | -10.8% | -75.2% | +0.0% | +0.0% | +0.0% | +80.8% | -13.3% | +1.4% | -71.8% | +246.4% | +99.8% | -299.6% | +110.6% |
| YoY Change | — | — | — | — | +195.3% | +74.3% | -77.9% | -75.2% | — | +80.8% | +56.8% | +58.9% | -75.2% | -1.0% | +95.1% | — | +46.6% |
Range-$664.50M – $485.50M
CAGR-16.7%
Avg YoY Growth+34.4%
Median YoY Growth+56.8%
Increase in accrued expenses and other liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's increase in accrued expenses and other liabilities?
- Vertex Pharmaceuticals (VRTX) reported increase in accrued expenses and other liabilities of $70.50M in Q1 2026.
- How has Vertex Pharmaceuticals's increase in accrued expenses and other liabilities changed year-over-year?
- Vertex Pharmaceuticals's increase in accrued expenses and other liabilities increased by 46.6% year-over-year, from $48.10M to $70.50M.
- What does increase in accrued expenses and other liabilities mean?
- The net change in expenses the company has incurred but not yet paid.